Todos Medical Confirms SARS-CoV-2 PCR Test Kits Us
Post# of 1418
(Total Views: 290)
Posted On: 11/30/2021 7:13:20 PM
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Provista to also utilize Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant
New York, NY, and Tel Aviv, ISRAEL, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has confirmed with its PCR test kit providers that the PCR test kits utilized at its CLIA/CAP certified lab Provista Diagnostics based in the Atlanta, GA area are able to detect a SARS-CoV-2 infection caused by the Omicron variant, as well as all other variants of concern, based on in silico analysis. Provista will also now be providing variant testing services utilizing Osang Healthcare’s Osang GeneFinder™ COVID-19 Variants-I RealAMP Kit (the “Osang Variant Kit”). The Osang Variant Kit has been confirmed to detect all known variants of concern, including Alpha, Beta, Gamma, Delta, Delta Plus and Omicron.
Todos sees a large market opportunity to gain market share based on the number of inquiries that are focused on Provista Diagnostics’ ability to screen for all variants including Omicron. The lab has reached another milestone as it has reached its COVID-19 PCR testing capacity of 20,000 tests daily. The company also has the capacity to do over 1,500 cPass tests per day, over 5,000 COVID variant tests per day, and over 5,000 respiratory panel tests per day when at full capacity. Given the current environment, the company is exploring the idea of purchasing more equipment to stay ahead of the curve with respect to surge capacity. Bringing on new customers without factoring in the ability to meet their needs with the coming surge could be considered irresponsible. Although the lab is not at full capacity, the pipeline projections could place the lab at capacity in the near future. Billing was a crucial part of the automation and the company is pleased to announce the receivables are turning. The business development team is also performing exceptionally well and may need additional capacity to sell in the near future.
“As we continue to build PCR testing volume at Provista, it is critical that we maintain the highest quality standards in helping physicians, patients and customers navigate the rapidly shifting COVID-19 testing landscape by confirming that our existing PCR test kits in use are able to identify the Omicron variant,” said Gerald E. Commissiong, President & CEO of Todos Medical. “The emerging Omicron variant has certainly caused global concern due to its potentially improved ability to escape protection provided by vaccine-induced neutralizing antibodies. In general, we know that newer more virulent SARS-CoV-2 variants can be neutralized with higher vaccine-induced neutralizing antibody titers than less virulent variants. With the Osang Variant Kit, we will begin offering high-capacity reflex reference lab testing services for our clients at Provista so that we can surveil which variants are responsible for positive tests. The turnaround time for the Osang Variant Kit assay is less than 3 hours in 96 or 384-well format, much shorter than the 24h+ it takes to complete genomic sequencing and with much greater capacity, and therefore we can scale variant surveillance using existing technologies in our own lab.”
https://investor.todosmedical.com/news-events...ts-used-at
Provista to also utilize Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant
New York, NY, and Tel Aviv, ISRAEL, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has confirmed with its PCR test kit providers that the PCR test kits utilized at its CLIA/CAP certified lab Provista Diagnostics based in the Atlanta, GA area are able to detect a SARS-CoV-2 infection caused by the Omicron variant, as well as all other variants of concern, based on in silico analysis. Provista will also now be providing variant testing services utilizing Osang Healthcare’s Osang GeneFinder™ COVID-19 Variants-I RealAMP Kit (the “Osang Variant Kit”). The Osang Variant Kit has been confirmed to detect all known variants of concern, including Alpha, Beta, Gamma, Delta, Delta Plus and Omicron.
Todos sees a large market opportunity to gain market share based on the number of inquiries that are focused on Provista Diagnostics’ ability to screen for all variants including Omicron. The lab has reached another milestone as it has reached its COVID-19 PCR testing capacity of 20,000 tests daily. The company also has the capacity to do over 1,500 cPass tests per day, over 5,000 COVID variant tests per day, and over 5,000 respiratory panel tests per day when at full capacity. Given the current environment, the company is exploring the idea of purchasing more equipment to stay ahead of the curve with respect to surge capacity. Bringing on new customers without factoring in the ability to meet their needs with the coming surge could be considered irresponsible. Although the lab is not at full capacity, the pipeline projections could place the lab at capacity in the near future. Billing was a crucial part of the automation and the company is pleased to announce the receivables are turning. The business development team is also performing exceptionally well and may need additional capacity to sell in the near future.
“As we continue to build PCR testing volume at Provista, it is critical that we maintain the highest quality standards in helping physicians, patients and customers navigate the rapidly shifting COVID-19 testing landscape by confirming that our existing PCR test kits in use are able to identify the Omicron variant,” said Gerald E. Commissiong, President & CEO of Todos Medical. “The emerging Omicron variant has certainly caused global concern due to its potentially improved ability to escape protection provided by vaccine-induced neutralizing antibodies. In general, we know that newer more virulent SARS-CoV-2 variants can be neutralized with higher vaccine-induced neutralizing antibody titers than less virulent variants. With the Osang Variant Kit, we will begin offering high-capacity reflex reference lab testing services for our clients at Provista so that we can surveil which variants are responsible for positive tests. The turnaround time for the Osang Variant Kit assay is less than 3 hours in 96 or 384-well format, much shorter than the 24h+ it takes to complete genomic sequencing and with much greater capacity, and therefore we can scale variant surveillance using existing technologies in our own lab.”
https://investor.todosmedical.com/news-events...ts-used-at
(0)
(0)